{"id":441288,"date":"2025-12-12T00:56:25","date_gmt":"2025-12-12T00:56:25","guid":{"rendered":"https:\/\/www.europesays.com\/us\/441288\/"},"modified":"2025-12-12T00:56:25","modified_gmt":"2025-12-12T00:56:25","slug":"should-everybody-be-taking-ozempic","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/441288\/","title":{"rendered":"Should everybody be taking Ozempic?"},"content":{"rendered":"<p><a class=\"\" href=\"https:\/\/www.cbc.ca\/radio\/frontburner\" target=\"_blank\" rel=\"noopener\">Front Burner<\/a><\/p>\n<p>We examine the rise and risks of blockbuster drugs like Ozempic, after the WHO conditionally recommended GLP-1s for the long-term treatment of obesity.\n<\/p>\n<p>CBC News  \u00b7 Posted: Dec 11, 2025 4:00 AM EST | Last Updated: December 11<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.cbc.ca\/a\/assets\/texttospeech.svg\" alt=\"Text to Speech Icon\" width=\"44\" height=\"44\"\/><\/p>\n<p>Listen to this article<\/p>\n<p>Estimated 1 minute<\/p>\n<p>The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results.<\/p>\n<p><img decoding=\"async\" loading=\"eager\" alt=\"Two boxes and a blue injector pen.\"   src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/12\/1765500985_865_default.jpg\" data-cy=\"leadmedia-story-img\" fetchpriority=\"high\"\/>Ozempic boxes and injector. (Turgut Yeter\/CBC)<strong>LISTEN | FRONT BURNER:<\/strong><\/p>\n<p>Front Burner25:34Should everybody be taking Ozempic?<\/p>\n<p>It&#8217;s estimated that as many as 10 per cent of adults in Canada use a GLP-1 type drug like Ozempic. The prescription medicine is used for type 2 diabetes management and increasingly prescribed off-label for weight loss. And this month, for the first time, the World Health Organization has conditionally recommended GLP-1 drugs for the long-term treatment of obesity.<\/p>\n<p>But while these drugs have been called a game-changing tool to manage a complex and stigmatized health condition, there\u2019s also a lot of questions about the potential negative impact.<\/p>\n<p>With Ozempic\u2019s patent set to expire soon in Canada, and more affordable generic options about to hit the market, a lot more people you know could end up on a weight-loss drug.<\/p>\n<p>Today we bring you the rise and risks of GLP-1s with help from Dylan Scott. He is a Senior Correspondent at Vox who covers health.<\/p>\n<p>For transcripts of Front Burner, please visit:\u00a0<a href=\"https:\/\/www.cbc.ca\/radio\/frontburner\/transcripts\" target=\"_blank\" rel=\"noopener\">https:\/\/www.cbc.ca\/radio\/frontburner\/transcripts<\/a><\/p>\n<p><strong>Subscribe to Front Burner on your favourite podcast app.<\/strong><\/p>\n<p><a href=\"https:\/\/itunes.apple.com\/ca\/podcast\/front-burner\/id1439621628?mt=2\" target=\"_blank\" rel=\"noopener\"><strong>Listen on Apple Podcasts<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/open.spotify.com\/show\/1qL9keKtruUmZ1hPkhHZL1\" target=\"_blank\" rel=\"noopener\"><strong>Listen on Spotify<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/youtube.com\/playlist?list=PLeyJPHbRnGaaAgINkiIQmNjTVRMB8RGI9&amp;si=g4Vxmp8msAKhGPPh\" target=\"_blank\" rel=\"noopener\"><strong>Listen on YouTube<\/strong><\/a>    <\/p>\n","protected":false},"excerpt":{"rendered":"Front Burner We examine the rise and risks of blockbuster drugs like Ozempic, after the WHO conditionally recommended&hellip;\n","protected":false},"author":3,"featured_media":441289,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[210,1060,67,132,68],"class_list":{"0":"post-441288","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115703879348895183","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/441288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=441288"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/441288\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/441289"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=441288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=441288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=441288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}